Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Protagonist Therapeutics is taking aim directly at Eli Lilly's obesity treatment with a newly announced drug that uses the same mechanism.

Eli Lilly's stock boomed April 17 after announcing a new experimental pill that caused nearly 8% weight loss at certain dosages and lowered blood sugar in patients during a clinical trial.. The ...

Eli Lilly (NYSE: LLY) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following recent clinical wins, the company may even be taking the lead ahead of ...

Eli Lilly said the investment will create 3,000 high-skilled positions and approximately 10,000 construction jobs. 3. Eli Lilly has unveiled plans to invest $27 billion in the construction of four ...

On Tuesday, Eli Lilly announced that it would start selling low doses of its weight-loss drug Zepbound in vials, too — at a far lower price than its pens, which come with pre-filled doses.

Eli Lilly saw its shares jump by 15% on Thursday after unveiling positive results from a clinical trial of its experimental oral drug. REUTERS Lilly’s stock was recently up 14% at $838.80 in ...

Eli Lilly Revenue Up on Demand for Mounjaro, Other Weight-Loss Meds The drug maker’s net income came in at $2.76 billion, or $3.06 a share, up from $2.24 billion, or $2.48 a share, in the prior ...

Eli Lilly’s revenue has grown at an average annual rate of 17.4% over the past three years (vs. 6.2% for the S&P 500) Revenue rose 32.0% from $34 billion to $45 billion over the past year (vs. 5 ...

Eli Lilly (NYSE:LLY) is a pharmaceutical titan with an $815 billion market cap, putting it on track to be the next $1 trillion stock and the first healthcare company to do so. Trading at $852 per ...

Eli Lilly LLY and AstraZeneca AZN are leading drugmakers with significant involvement in oncology, immunology, and the cardiometabolic disease space.Both are making substantial investments in next ...

Eli Lilly, the drugmaker behind the blockbuster weight loss drug Zepbound, is suing four telehealth companies for allegedly selling illegal copies of the drug made by compounding pharmacies ...